AMN Healthcare's (AMN) dismal results in the majority of its segments led to a soft overall first-quarter performance.
Haemonetics (HAE) Q4 revenues were driven by an uptick in the Plasma and Hospital segments.
Catalent (CTLT) reports a solid revenue uptick in third-quarter fiscal 2024 despite lower revenues in Biologics segments.